High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [8]

New England Journal of Medicine

Volumn 358, Issue 1, 2008, Pages 91-92

  Lachmann, Helen J ^a   Wechalekar, Ashutosh D ^a   Gillmore, Julian D ^a  

^a National Amyloidosis Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; MYELOABLATIVE AGENT;

AMYLOIDOSIS; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; HUMAN; LETTER; MONOTHERAPY; NORTH AMERICA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM; DRUG COMBINATION; MORTALITY; NOTE; RISK;

AMYLOIDOSIS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; MYELOABLATIVE AGONISTS; RISK;

EID: 38049059363     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc072918     Document Type: Letter

References (2)

1. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-64.
2. Guidelines Working Group of UK Myeloma Forum, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004;125:681-700.